BMI and Intermittent Fasting: What You Need to Know

BMI and intermittent fasting are closely linked concepts in weight management, with BMI providing a measurable starting point and intermittent fasting offering a structured approach to reducing calorie intake. Understanding how your BMI relates to fasting can help you set realistic goals, identify whether a dietary change is appropriate, and monitor your progress safely. This article explains how BMI is calculated and interpreted under NHS and NICE guidance, how intermittent fasting works in the body, who should exercise caution, and how to track your health effectively while following a fasting plan.

What is BMI and why does it matter for weight management?

BMI categorises weight status using standard NHS thresholds and helps identify health risks such as type 2 diabetes and cardiovascular disease, though it should be used alongside waist circumference for a more complete assessment.

Body mass index (BMI) is a numerical measure calculated by dividing a person's weight in kilograms by the square of their height in metres, and it is widely used in clinical practice to categorise weight status. In the UK, the NHS uses the following standard thresholds for adults:

• Below 18.5: underweight

• 18.5 to 24.9: healthy weight

• 25 to 29.9: overweight

• 30 and above: obese

For people from South Asian, Chinese, Black African or African-Caribbean backgrounds, NICE guidance notes that health risks may occur at lower BMI thresholds. In UK practice, a BMI of 23 or above may indicate increased risk and a BMI of 27.5 or above may indicate high risk in these groups, compared with the standard 25 and 30 thresholds used for white European adults. Clinicians may apply these adjusted cut-off points accordingly.

BMI matters for weight management because it provides a consistent, reproducible starting point for assessing health risk and eligibility for interventions. Higher BMI is associated with increased risk of type 2 diabetes, cardiovascular disease, certain cancers and musculoskeletal conditions.^[4] However, BMI is not a perfect tool: it does not distinguish between fat mass and muscle mass, and it does not account for where fat is distributed in the body. It is also less reliable during pregnancy or in people with very high muscle mass. Waist circumference is therefore often measured alongside BMI to give a more complete picture of metabolic risk. NHS guidance suggests that a waist circumference above 94 cm in men or above 80 cm in women indicates increased risk, with thresholds of 102 cm and 88 cm respectively indicating high risk; lower cut-offs apply for some ethnic groups.^[7][8]

Understanding your BMI is a useful first step before beginning any dietary approach, including intermittent fasting. It helps you and a healthcare professional set realistic goals, identify whether a structured intervention is appropriate, and monitor change over time. If you are unsure of your BMI or what it means for your health, speaking to your GP or a registered dietitian is a sensible starting point.

How does intermittent fasting actually work in the body?

Intermittent fasting depletes glycogen stores and triggers lipolysis, drawing on fat for energy; it reduces BMI primarily by helping people lower overall calorie intake rather than through a unique metabolic mechanism.

Intermittent fasting reduces calorie intake by restricting the window during which food is consumed, and this creates a metabolic shift that the body uses stored energy to compensate for. Rather than specifying which foods to eat, intermittent fasting focuses on when eating occurs. Common approaches include:

• The 16:8 method: eating within an eight-hour window and fasting for sixteen hours each day

• The 5:2 method: eating normally for five days and restricting calorie intake substantially on two non-consecutive days per week (the British Dietetic Association notes a commonly cited target of around 500 to 600 kilocalories on restricted days, though individual plans may vary)

• Alternate-day fasting: alternating between unrestricted eating days and fasting or very low-calorie days

During a fasting period, once glycogen stores in the liver are depleted, the body begins to draw on fat stores for energy through a process called lipolysis. The point at which this shift occurs varies between individuals depending on factors such as prior food intake, activity level and metabolic rate; it does not occur at a fixed number of hours for everyone. This process can lead to a reduction in body fat over time, which in turn may lower BMI. Some research also suggests that intermittent fasting may improve insulin sensitivity, reduce inflammatory markers and support favourable changes in blood lipid profiles, though findings vary across studies and the evidence base continues to evolve.^[14][15]

It is important to note that the weight loss achieved through intermittent fasting is broadly comparable to that achieved through continuous calorie restriction when total calorie intake is matched.^[9][10] The approach works primarily because it helps many people reduce overall energy intake more easily than counting calories at every meal. Individual responses vary considerably, and intermittent fasting is not a metabolic shortcut: the quality and quantity of food consumed during eating windows still matters significantly for overall health outcomes.

What does the NHS and NICE guidance say about intermittent fasting?

Neither the NHS nor NICE recommends intermittent fasting as a first-line treatment, but neither prohibits it for healthy adults; NICE prioritises multicomponent lifestyle interventions for weight management.

Neither the NHS nor NICE currently recommends intermittent fasting as a first-line or standard treatment for weight management, though neither body prohibits it for healthy adults who choose to follow it. NICE guidance on obesity and weight management focuses primarily on multicomponent lifestyle interventions that combine dietary change, increased physical activity and behavioural support. These remain the cornerstone of NHS-supported weight management programmes.

The NHS does acknowledge that different dietary approaches, including time-restricted eating, may suit different individuals, and that the most effective diet is one a person can sustain over the long term. NHS guidance emphasises that any dietary change should be nutritionally balanced and should not lead to deficiencies in essential vitamins, minerals or macronutrients.

For people with a BMI of 30 or above (or 27.5 and above for certain ethnic groups), NICE recommends referral to structured weight management services. Where lifestyle interventions alone are insufficient, pharmacological treatment may be considered. Tirzepatide (Mounjaro) is authorised by the MHRA for both type 2 diabetes and chronic weight management in the UK, and semaglutide (Wegovy) is similarly authorised for weight management.^[16][17] Both medicines have been appraised by NICE for their weight management indications and are recommended under specific eligibility criteria set out in the relevant NICE technology appraisals. Access through the NHS is subject to local commissioning decisions by Integrated Care Boards (ICBs), and local pathways and tiered services determine referral routes in practice. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a prescriber may consider appropriate options after a clinical assessment.

If you are considering combining intermittent fasting with a medically supervised weight management plan, discussing this with your GP or a registered dietitian ensures the approach is safe and appropriate for your individual circumstances.

Who should be cautious about intermittent fasting?

People with diabetes, eating disorders, those who are pregnant, underweight, or taking medications such as insulin, SGLT2 inhibitors or sulfonylureas should seek medical advice before fasting.

Intermittent fasting is not suitable for everyone, and certain groups should seek medical advice before starting any fasting regimen. People who should exercise particular caution or avoid intermittent fasting without professional guidance include:

• People with type 1 or type 2 diabetes, particularly those taking insulin or sulfonylureas, as fasting can increase the risk of hypoglycaemia

• People with type 2 diabetes taking SGLT2 inhibitors (such as dapagliflozin or empagliflozin), as prolonged fasting or very low carbohydrate intake can increase the risk of euglycaemic diabetic ketoacidosis (DKA), a serious condition that can occur even when blood glucose appears normal.^[19][20] The MHRA has issued a Drug Safety Update on this risk; anyone taking an SGLT2 inhibitor should seek medical advice before fasting^[19][20]

• People with a history of eating disorders, including anorexia nervosa, bulimia nervosa or binge eating disorder, as restrictive eating patterns may trigger or worsen disordered eating behaviours

• People who are pregnant or breastfeeding, for whom adequate and consistent nutrition is essential

• Children and adolescents, whose nutritional needs during growth and development make calorie restriction inappropriate without specialist oversight

• People who are underweight (BMI below 18.5), for whom further calorie restriction carries significant health risks

• People taking certain medications, including those where food timing affects absorption or safety, such as insulin, sulfonylureas, higher doses of rivaroxaban (15 mg and 20 mg, which should be taken with food), bisphosphonates, and medicines that can irritate the stomach such as non-steroidal anti-inflammatory drugs or corticosteroids^[23][24]

Older adults should also approach intermittent fasting with care, as inadequate protein intake during restricted eating windows can accelerate age-related muscle loss (sarcopenia), which in turn affects mobility and metabolic health.^[26]

If you experience symptoms such as persistent dizziness, fainting, severe headaches, heart palpitations or significant mood disturbance while following a fasting plan, you should stop fasting and contact your GP. People with diabetes who develop symptoms such as abdominal pain, nausea, vomiting or rapid breathing should seek urgent medical attention, as these may indicate DKA. For urgent concerns, NHS 111 can provide advice. Always inform your GP or pharmacist of any dietary changes if you are taking regular medication.

How to track your progress safely while following a fasting plan

Progress should be tracked using consistent weekly weigh-ins, waist circumference measurements, and monitoring of energy, mood and sleep, with periodic GP review recommended for those with obesity or underlying health conditions.

Tracking progress during intermittent fasting should go beyond monitoring weight alone, as BMI and body weight are only part of the picture when assessing the health impact of dietary change. A more complete approach to monitoring includes:

• Weighing yourself consistently, ideally at the same time of day and on the same day each week, to reduce the effect of normal daily fluctuations

• Measuring waist circumference, which reflects visceral fat more directly than BMI and is a useful complement to weight tracking. NHS guidance suggests risk thresholds of 94 cm for men and 80 cm for women, with lower cut-offs for some ethnic groups

• Monitoring energy levels, sleep quality and mood, as these can indicate whether the fasting pattern is sustainable and nutritionally adequate

• Keeping a food diary during eating windows, to ensure meals are balanced and provide sufficient protein, fibre, vitamins and minerals

NHS guidance on safe weight loss suggests that losing around 0.5 to 1 kilogram (approximately 1 to 2 pounds) per week is a realistic and sustainable rate for most people. Faster weight loss may indicate excessive calorie restriction, which can lead to muscle loss, nutrient deficiencies and fatigue.

If you have a BMI in the obese range or have underlying health conditions, periodic review with a GP or practice nurse is advisable. Blood tests to check glucose, lipids and nutritional markers may be appropriate depending on your individual circumstances. Apps and wearable devices can support self-monitoring, but they should complement rather than replace professional review.

Finally, it is worth remembering that intermittent fasting is a tool, not a guarantee. Sustainable weight management typically requires a combination of dietary change, regular physical activity and, where appropriate, behavioural or medical support. If progress stalls or you find the approach difficult to maintain, speaking to a healthcare professional can help you explore alternatives.

Scientific References

1. Calculate your body mass index (BMI).
2. Overweight and obesity management (NG246) – Identifying and assessing overweight, obesity and central adiposity.
3. Overweight and obesity in adults.
4. Overweight and obesity management (NG246) – Context.
5. Overweight and obesity management (NG246) – Discussing results and referral.
6. Overweight and obesity management (NG246) – Appendix A1: Summary of evidence from surveillance.
7. Calculate your waist to height ratio.
8. Waist circumference as a measure for indicating need for weight management.
9. Is Fasting Superior to Continuous Caloric Restriction for Weight Management?.
10. Calorie Restriction with or without Time-Restricted Eating in Type 2 Diabetes.
11. Intermittent fasting for adults with overweight or obesity.
12. Intermittent fasting versus continuous energy-restricted diet for patients with type 2 diabetes mellitus and metabolic syndrome for glycemic control.
13. Intermittent versus continuous energy restriction on weight loss and cardiometabolic outcomes: a systematic review and meta-analysis.
14. The effect of intermittent fasting on insulin resistance, lipid profiles and inflammatory markers.
15. Time-Restricted Eating in Metabolic and Clinical Health: Current Evidence and Mechanistic Insights.
16. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
17. Tirzepatide: a medicine to manage type 2 diabetes and obesity.
18. MHRA approves GLP-1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults.
19. SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis.
20. SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness.
21. Life-threatening dapagliflozin-associated euglycaemic diabetic ketoacidosis in a postoperative patient.
22. Clinical and biochemical characteristics and analysis of risk factors for euglycaemic diabetic ketoacidosis in type 2 diabetic individuals treated with SGLT2 inhibitors.
23. Xarelto 20 mg film-coated tablets (rivaroxaban) – Summary of Product Characteristics.
24. Rivaroxaban (Xarelto): reminder that 15 mg and 20 mg tablets should be taken with food.
25. Rivaroxaban | Drugs | BNF – NICE.
26. Addressing sarcopenia – British Dietetic Association.
27. Tips to help you lose weight.

Frequently Asked Questions